Latest news
25 items- PRAligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
- SECSEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.15-12B - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- SECSEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- SECSEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- SECSEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- SECSEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- INSIDERSEC Form 4: Koppel Adam closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Zeng Ling closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Weissman James B closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Smith Cynthia closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Pagan Douglas W. closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Kozin Marc D returned $433,487 worth of shares to the company (11,333 units at $38.25), closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Hoffman Stephen J closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Gray Patrick M. closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Freed Martin I closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Fambrough Douglas returned $8,852,236 worth of shares to the company (231,431 units at $38.25), closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Doberstein Stephen K closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Ciappenelli Robert D. closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Buchi J Kevin closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Brown Bob D closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- INSIDERSEC Form 4: Aradhye Shreeram closing all direct ownership in the company4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
- SECSEC Form POSASR filed by Dicerna Pharmaceuticals, Inc.POSASR - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- SECSEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- SECSEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
- SECSEC Form POS AM filed by Dicerna Pharmaceuticals, Inc.POS AM - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
DRNA FAQ
7 questionsWhat does Dicerna Pharmaceuticals, Inc. do?
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus...Where does DRNA stock trade?
Dicerna Pharmaceuticals, Inc. (DRNA) is listed on NASDAQ.What sector and industry is DRNA in?
Dicerna Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Dicerna Pharmaceuticals, Inc. go public?
Dicerna Pharmaceuticals, Inc. (DRNA) completed its IPO in 2014.What are analysts saying about DRNA?
Dicerna Pharmaceuticals, Inc. has had 8 recent analyst actions on file. The most recent action was from Chardan Capital: Neutral with a $3825.00 price target on 2021-12-09. Recent price targets range from $2500.00 to $3825.00.What companies are similar to DRNA?
Notable peers in the same industry include TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), KIN (Kindred Biosciences, Inc.). Compare DRNA side-by-side with any of them on Quantisnow.How can I track DRNA on Quantisnow?
Quantisnow aggregates Dicerna Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRNA to receive live email and push alerts on every new disclosure.